Results 11 to 20 of about 2,247 (204)
Pharmacokinetics and Pharmacodynamics of Tedizolid [PDF]
Clinical Pharmacokinetics, 2022 Tedizolid is an oxazolidinone antibiotic with high potency against Gram-positive bacteria and currently prescribed in bacterial skin and skin-structure infections. The aim of the review was to summarize and critically review the key pharmacokinetic and pharmacodynamic aspects of tedizolid.
Khalid Iqbal +2 more
openaire +3 more sources
Thrombocytopenia with Tedizolid and Linezolid [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we ...
Lee, Erica Yookyung, Caffrey, R
openaire +5 more sources
Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections [PDF]
Brazilian Journal of Infectious Diseases, 2016 Acute bacterial skin and skin structure infections are caused mainly by Gram-positive bacteria which are often treated with intravenous vancomycin, daptomycin, or linezolid, with potential step down to oral linezolid for outpatients.
Alejandro Ortiz-Covarrubias +9 more
doaj +2 more sources
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections [PDF]
Drug Design, Development and Therapy, 2013 Olatz Urbina,1 Olivia Ferrández,1 Mercè Espona,1 Esther Salas,1 Irene Ferrández,2 Santiago Grau1 1Services of Hospital Pharmacy, Hospital Universitari del Mar, Universitat Autònoma de Barcelona, 2Ciència i Tecnologia ...
Urbina O +5 more
doaj +3 more sources
Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs [PDF]
Antibiotics, 2021 Background: To evaluate the efficacy and safety of long-term use of tedizolid in osteoarticular infections. Methods: Multicentric retrospective study (January 2017–March 2019) of osteoarticular infection cases treated with tedizolid.
Eva Benavent +9 more
doaj +2 more sources
In Vitro Activity of Tedizolid against Mycobacterium tuberculosis [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Tedizolid is a novel oxazolidinone with activities against Gram-positive microorganisms, including mycobacteria. We studied the in vitro activity of tedizolid against 120 Mycobacterium tuberculosis strains, including susceptible, first-line-resistant, and multidrug-resistant isolates.
Ruiz Martínez, P. +3 more
openaire +7 more sources
Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats
European Journal of Drug Metabolism and Pharmacokinetics, 2023 Therapeutic drug monitoring (TDM) is an effective tool for the management of patients who are administered linezolid. The use of saliva for TDM has potential advantages over the use of plasma; however, only a few reports have compared drug concentrations in the saliva and plasma. Moreover, there are no reports on the salivary concentration of tedizolid,
Yuki Inoue +5 more
openaire +4 more sources
Infection and Drug Resistance, 2015 Ronald G Hall 2nd, Heidi N Michaels Texas Tech University Health Sciences Center, Dallas, TX, USA Abstract: Tedizolid phosphate is the first once-daily oxazolidinone approved by the United States Food and Drug Administration for the treatment of acute ...
Hall RG 2nd, Michaels HN
doaj +1 more source
Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
Drug Design, Development and Therapy, 2016 Olivia Ferrández,1,2 Olatz Urbina,1 Santiago Grau1,3 1Hospital Pharmacy, Hospital Universitari del Mar, Barcelona, Spain; 2Nursing Department, Universitat Pompeu Fabra, Barcelona, Spain; 3Medicine Department, Universitat Autònoma de ...
Ferrández O, Urbina O, Grau S
doaj +1 more source
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
Infection and Drug Resistance, 2022 Huiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center
Zhang H +7 more
doaj +3 more sources